Drug name - Orkambi

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8754224 VERTEX PHARMS INC Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
Dec, 2026

(4 years from now)

US7495103 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
May, 2027

(4 years from now)

US10597384 VERTEX PHARMS INC Solid forms of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
Dec, 2028

(6 years from now)

US8507534 VERTEX PHARMS INC Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
Sep, 2030

(7 years from now)

CN102652128A VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Mar, 2015

(7 years ago)

CN101006076B VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN104788328A VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN104788328B VERTEX PHARMS INC Atp-Binding Cassette Transport Protein Modulators
Jun, 2025

(2 years from now)

CN101935301B VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN103641765A VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN101006076A VERTEX PHARMS INC Regulator Of Atp-Abc Transport Protein
Jun, 2025

(2 years from now)

CN107501099A VERTEX PHARMS INC Atp-Binding Cassette Transport Protein Modulators
Jun, 2025

(2 years from now)

CN101891680B VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN107501099B VERTEX PHARMS INC Modulator Of Atp-Binding Cassette Transport Protein
Jun, 2025

(2 years from now)

CN103641765B VERTEX PHARMS INC Atp-Binding Cassette Transport Proteins Regulating Agent
Jun, 2025

(2 years from now)

CN101935301A VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN101891680A VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN101384172B VERTEX PHARMS INC N - (2, 4 - (1, 1 - - Dimethyl Ethyl) -5 - Phenyl] -1, 4 - - Dihydro - -4--- Oxo-Quinoline -3 - Formamide In Solid Form
Dec, 2026

(4 years from now)

CN101384172A VERTEX PHARMS INC Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

CN103626744B VERTEX PHARMS INC Solid Forms Of 3-(6-(1-(2,2-Difluorobenzo[D][1,3] Dioxol-5-Yl) Cyclopropanecarboxamido)-3-Methylpyridin-2-Yl) Benzoic Acid
Dec, 2028

(6 years from now)

CN101910156A VERTEX PHARMS INC Solid Forms Of 3-(6-(1-(2,2-Difluorobenzo[D][1,3] Dioxol-5-Yl) Cyclopropanecarboxamido)-3-Methylpyridin-2-Yl) Benzoic Acid
Dec, 2028

(6 years from now)

CN103626744A VERTEX PHARMS INC Solid Forms Of 3-(6-(1-(2,2-Difluorobenzo[D][1,3] Dioxol-5-Yl) Cyclopropanecarboxamido)-3-Methylpyridin-2-Yl) Benzoic Acid
Dec, 2028

(6 years from now)

CN101910156B VERTEX PHARMS INC Solid Forms Of 3-(6-(1-(2,2-Difluorobenzo[D][1,3] Dioxol-5-Yl) Cyclopropanecarboxamido)-3-Methylpyridin-2-Yl) Benzoic Acid
Dec, 2028

(6 years from now)

IN282654B VERTEX PHARMS INC Modulators Of Atpbinding Cassette Transporters
Jun, 2025

(2 years from now)

EP1773816B1 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jul, 2020

(2 years ago)

EP1773816A2 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jul, 2020

(2 years ago)

EP2502911A3 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP3216787A1 VERTEX PHARMS INC Intermediates For The Preparation Of Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP2489659B1 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP2489659A1 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP2502911B1 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP3216787B1 VERTEX PHARMS INC Intermediates For The Preparation Of Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP2502911A2 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP1993360A4 VERTEX PHARMS INC Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP1993360A2 VERTEX PHARMS INC Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP1993360B1 VERTEX PHARMS INC Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP3219705A1 VERTEX PHARMS INC Pharmaceutical Compositions Of The Amorphous Form Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP3219705B1 VERTEX PHARMS INC Pharmaceutical Compositions Of The Amorphous Form Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP2225230A1 VERTEX PHARMS INC Solid Forms Of 3-(6-(1-(2,2-Difluorobenzo[D][1,3]Dioxol-5-Yl) Cyclopropanecarboxamido)-3-Methylpyridin-2-Yl) Benzoic Acid
Dec, 2028

(6 years from now)

EP2225230B1 VERTEX PHARMS INC Solid Forms Of 3-(6-(1-(2,2-Difluorobenzo[D][1,3]Dioxol-5-Yl) Cyclopropanecarboxamido)-3-Methylpyridin-2-Yl) Benzoic Acid
Dec, 2028

(6 years from now)

EP3170818B1 VERTEX PHARMS INC Solid Forms Of 3-(6-(1-(2,2-Difluorobenzo[D][1,3]Dioxol-5-Yl) Cyclopropanecarboxamido)-3-Methylpyridin-2-Yl) Benzoic Acid
Dec, 2028

(6 years from now)

EP3170818A1 VERTEX PHARMS INC Solid Forms Of 3-(6-(1-(2,2-Difluorobenzo[D][1,3]Dioxol-5-Yl) Cyclopropanecarboxamido)-3-Methylpyridin-2-Yl) Benzoic Acid
Dec, 2028

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8741933 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters Nov, 2026

(4 years from now)

US7973038 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters Nov, 2026

(4 years from now)

US9216969 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters Nov, 2026

(4 years from now)

US9931334 VERTEX PHARMS INC Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide Dec, 2026

(4 years from now)

US8410274 VERTEX PHARMS INC Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide Dec, 2026

(4 years from now)

US9670163 VERTEX PHARMS INC Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide Dec, 2026

(4 years from now)

US8324242 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters Aug, 2027

(4 years from now)

US8653103 VERTEX PHARMS INC Solid forms of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid Dec, 2028

(6 years from now)

US9150552 VERTEX PHARMS INC Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid Dec, 2028

(6 years from now)

US10076513 VERTEX PHARMS INC Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof Dec, 2028

(6 years from now)

US11052075 VERTEX PHARMS INC Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof Dec, 2028

(6 years from now)

US8846718 VERTEX PHARMS INC Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxo1-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid Dec, 2028

(6 years from now)

US10646481 VERTEX PHARMS INC Pharmaceutical composition and administrations thereof Aug, 2029

(6 years from now)

US9192606 VERTEX PHARMS INC Dosage units of 3-(6-(1-(2,2-difluorobenzo[d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid Sep, 2029

(7 years from now)

US8716338 VERTEX PHARMS INC Dosage units of 3-(6-(1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid Sep, 2030

(7 years from now)

US8993600 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters Dec, 2030

(8 years from now)

Drugs and Companies using IVACAFTOR; LUMACAFTOR ingredient

Treatment: Method of treating cystic fibrosis in a patient, the patient having the f508del mutation in cftr, using ivacaftor and lumacaftor; method of treating cystic fibrosis in patients who are homozygous for the f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene; Method of treating cystic fibrosis using n-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide and 3-(6-(1-2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid; Treatment of cystic fibrosis in a patient age 2-5 years who is homozygous for the f508del mutation in the cftr gene using lumacaftor and a solid composition comprising amorphous and less than about 30% crystalline ivacaftor; Method of treating a patient having cystic fibrosis using ivacaftor and lumacaftor; Method of treating a patient having cystic fibrosis using ivacaftor and lumacaftor; method of treating cystic fibrosis; Treatment of cystic fibrosis in a patient age 2-5 years who is homozygous for the f508del mutation in the cftr gene using lumacaftor form i and ivacaftor; Treatment of cystic fibrosis in a patient age 12 years or older who is homozygous for the f508del mutation in the cftr gene using the tablet comprising lumacaftor as recited in claim 1, 19, or 21 of u.s. patent no. 10,076,513 and ivacaftor; Treatment of cystic fibrosis in patients 6 years and older who are homozygous for the f508del mutation in the cftr gene using the tablet according to claim 1 of u.s. patent no. 11,052,075, where the tablet further comprises ivacaftor; Method of treating cystic fibrosis in patients who are homozygous for the f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene; method of treating cystic fibrosis in a patient, the patient having the f508del mutation in cftr, using ivacaftor and form i lumacaftor; Treatment of cystic fibrosis in a patient age 2-5 years who is homozygous for the f508del mutation in the cftr gene using the dosage unit comprising lumacaftor and ivacaftor as recited in claim 1 of us patent 9192606; Method of treating cystic fibrosis in a patient, the patient having the f508del mutation in cftr, using the dosage unit of claim 1 of u.s. patent no. 8,716,338; method of treating cystic fibrosis in patients who have the f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.

Dosage: GRANULE;ORAL

More Information on Dosage
Strength Dosage Availability
125MG/PACKET;100MG/PACKET GRANULE;ORAL Prescription
188MG/PACKET;150MG/PACKET GRANULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.